Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
480 participants
OBSERVATIONAL
2008-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This clinical trial is studying biomarkers to see how well they predict heart dysfunction in women with breast cancer treated with trastuzumab.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Primary
* To prospectively evaluate whether an increase in cardiac biomarker levels can predict cardiac dysfunction in women with HER2/neu-positive breast cancer treated with trastuzumab as curative intent.
Secondary
* To develop a predictive model for use in this patient population based on the most accurate and sensitive combination of biomarkers.
This is an observational study with all patients having
* Blood tests for BNP, Nt-pro BNP, CRP and Troponin-T every 42 days (6 weeks) whilst on treatment with chemotherapy and/or Trastuzumab.
* Echocardiograph or MUGA before treatment, after completion of anthracycline therapy where applicable, and every twelve weeks whilst on Trastuzumab. Assessment of ejection fraction may be carried out at any time for symptoms. All Echocardiographs and MUGAs will be carried out locally. 2-D Echocardiograph is the preferred method for assessment of LVEF. Where possible, the same cardiac imaging facility should be used for all LVEF assessments. A sample study from each participating institution will be reviewed by the principal investigating cardiologist. Results of left ventricular function assessment will be used to make treatment decisions as normal. Managing clinicians will not be made aware of the results of biomarker assessments, thus this study is blinded.
* Cardiorespiratory symptom assessment, ECOG score, vitals, weight and NYHA (if applicable) prior to each dose of anthracyclines and every 6 weeks whilst on Paclitaxel-trastuzumab and on single agent Trastuzumab.
Patients on BETH :
The LVEF monitoring sequence required by CADY will be altered to parallel that required by BETH. Thus, echocardiograph or MUGA will be carried out according to the BETH cardiac safety monitoring protocol. This altered schedule applies only to patients enrolled in both studies. Of note, for patients on the BETH study, all LVEF assessments must be performed by the same method used at baseline.
Patients on ALTTO:
It is possible that a patient who is enrolled on both CADY and ALLTO may not eventually receive Trastuzumab. Nonetheless, as Lapatinib is also associated with a risk of cardiotoxicity, such patients should remain on study whilst receiving single agent Lapatinib. The schedule of on study assessments will be identical to that of patients receiving Trastuzumab.
For patients enrolled in both studies, the LVEF monitoring sequence required by CADY will be altered to parallel that required by ALLTO. Thus, echocardiograph or MUGA will be carried out according to the ALLTO cardiac safety monitoring protocol Of note, for patients on the ALLTO study, all LVEF assessments must be performed by the same method used at baseline.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
trastuzumab
laboratory biomarker analysis
assessment of therapy complications
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Planned neoadjuvant and/or adjuvant treatment with chemotherapy and Trastuzumab either sequentially or in combination or single agent Trastuzumab.
3. 18 years of age or older.
4. Disease Stage I-III, whose treatment plan includes Trastuzumab either sequentially, in combination or as a single agent will be eligible for inclusion in the study.
5. As this is a non-interventional study, patients enrolled in therapeutic clinical trials will also be eligible for inclusion.
6. Treatment with curative intent.
7. ECOG Performance status 0, 1 or 2.
8. Adequate cardiac function, with MUGA or Echocardiograph \> 50%.
9. Written informed consent.
Exclusion Criteria
2. Evidence of metastatic disease.
3. Patients with uncontrolled hypertension (sustained systolic blood pressure \>180mmHg or diastolic blood pressure \>100mmHg), significant valvular disease (aortic or mitral regurgitation of 3 or 4+/ 4+ severity or stenosis of either valve), history of uncontrolled cardiac arrhythmias, prior symptomatic or asymptomatic myocardial infarction or angina pectoris requiring anti-anginal medication.
4. Prior anthracycline or Trastuzumab therapy.
5. Inability to give informed consent for any reason.
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cancer Trials Ireland
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ray McDermott, MD
Role: PRINCIPAL_INVESTIGATOR
Adelaide and Meath Hospital, Dublin Incorporating the National Children's Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Bons Secours Hospital
Cork, , Ireland
Cork University Hospital
Cork, , Ireland
Our Ladies of Lourdes Hospital
Drogheda, , Ireland
Adelaide and Meath Hospital, Dublin Incorporating the National Children's Hospital
Dublin, , Ireland
St. Vincent's University Hospital
Dublin, , Ireland
Mater Misericordiae University Hospital
Dublin, , Ireland
St. James's Hospital
Dublin, , Ireland
Beaumont Hospital
Dublin, , Ireland
Mater Private Hospital
Dublin, , Ireland
University College Hospital
Galway, , Ireland
Letterkenny General Hospital
Letterkenny, , Ireland
Mid- Western Regional Hospital
Limerick, , Ireland
Sligo General Hospital
Sligo, , Ireland
Waterford Regional Hospital
Waterford, , Ireland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ICORG-08-01
Identifier Type: -
Identifier Source: secondary_id
EU-20948
Identifier Type: -
Identifier Source: secondary_id
08-01 ICORG
Identifier Type: -
Identifier Source: org_study_id